弥漫性中线胶质瘤的内在与环境特征:对开发有效免疫治疗策略的意义
弥漫性中线胶质瘤(DMG)是儿童中枢神经系统最致命的肿瘤,姑息性放疗是唯一证实有效的治疗选择,但生存期仅暂时延长。DMG具有免疫「冷」肿瘤微环境(TME),免疫检查点蛋白低表达、独特表观遗传特征、低肿瘤突变负荷及反复体细胞突变可能降低传统免疫治疗疗效。本文综述免疫治疗局限,强调过继细胞转移和溶瘤病毒等新兴疗法的安全性与临床疗效,以及DMG-免疫轴知识进展,以指导免疫治疗开发。
要点
- DMG包括脑干弥漫性内生型脑桥胶质瘤,是儿童中枢神经系统最致命肿瘤,姑息性放疗仅暂时延长生存。
- DMG为免疫「冷」TME,免疫检查点蛋白PD-1、PD-L1、CTLA-4低表达,可能致免疫检查点抑制剂无响应。
- 独特表观遗传特征、低肿瘤突变负荷及H3K27M等体细胞突变可能降低传统免疫治疗疗效。
核心结论
- DMG是最致命的儿童癌症,姑息性放疗为唯一证实有效的治疗选择,但生存仅暂时延长。
- DMG免疫「冷」TME及低免疫检查点蛋白表达可能致免疫检查点抑制剂缺乏响应。
- 过继细胞转移(包括嵌合抗原受体T细胞)和溶瘤病毒正在评估用于DMG治疗。
- 提高对DMG内在和TME特征的理解对患者从这些复杂治疗中获益至关重要。
研究设计与样本
- 综述:总结免疫治疗方法的局限性,强调基于细胞的复杂疗法的新兴安全性和临床疗效,以及DMG-免疫轴的知识进展。
主要发现
- DMG具有免疫「冷」TME,浸润免疫细胞少,机制未完全明了。
- PD-1、PD-L1和CTLA-4等免疫检查点蛋白低表达是DMG反复出现的特征,可能致免疫检查点抑制剂缺乏响应。
- 独特表观遗传特征(包括干细胞样甲基化模式)、低肿瘤突变负荷及反复体细胞突变(H3K27M、TP53、ACVR1、MYC和PIK3CA)可能降低传统免疫治疗疗效。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Diffuse midline glioma (DMG), including those of the brainstem (diffuse intrinsic pontine glioma), are pediatric tumors of the central nervous system (CNS). Recognized as the most lethal of all childhood cancers, palliative radiotherapy remains the only proven treatment option, however, even for those that respond, survival is only temporarily extended. DMG harbor an immunologically "cold" tumor microenvironment (TME) with few infiltrating immune cells. The mechanisms underpinning the cold TME are not well understood. Low expression levels of immune checkpoint proteins, including PD-1, PD-L1, and CTLA-4, are recurring features of DMG and likely contribute to the lack of response to immune checkpoint inhibitors (ICIs). The unique epigenetic signatures (including stem cell-like methylation patterns), a low tumor mutational burden, and recurring somatic mutations (H3K27M, TP53, ACVR1, MYC, and PIK3CA), possibly play a role in the reduced efficacy of traditional immunotherapies. Therefore, to circumvent the lack of efficacy thus far seen for the use of ICIs, adoptive cell transfer (including chimeric antigen receptor T cells) and the use of oncolytic viruses, are currently being evaluated for the treatment of DMG. It remains an absolute imperative that we improve our understanding of DMG's intrinsic and TME features if patients are to realize the potential benefits offered by these sophisticated treatments. Herein, we summarize the limitations of immunotherapeutic approaches, highlight the emerging safety and clinical efficacy shown for sophisticated cell-based therapies, as well as the evolving knowledge underpinning the DMG-immune axis, to guide the development of immunotherapies that we hope will improve outcomes.
引用
- Persson ML, Douglas AM, Alvaro F, et al. The intrinsic and microenvironmental features of diffuse midline glioma: Implications for the development of effective immunotherapeutic treatment strategies. Neuro Oncol. 2022. PMID: 35481923. doi:10.1093/neuonc/noac117
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。